NASDAQ · VRXA
Veraxa Biotech AG - Post de-SPAC
Last insider buy price $1.00 Paid by Director Marc Gruninger on Oct 28 (Form 4). Not today's price.
Smart money pulse
What insiders and funds are doing
Buying Insiders: as of Nov 12 Funds: as of Jun 30, 2026
- group1 insider bought in the last 30 days. $9.98K in open-market buys, Oct 27–28.
- infoNo real insider sales in 12 months. Planned 10b5-1 sales and tax withholding are left out.
−100 means everyone selling, +100 everyone buying. This is data, not advice.
How the Pulse works
Pulse runs from −100 (everyone selling) to +100 (everyone buying). Half comes from insiders: real buyers vs. real sellers in the last 90 days (Form 4). Half comes from funds: funds that bought vs. funds that sold last quarter (13F). 13F is a snapshot of long positions on the last day of the quarter, filed up to 45 days later. It does not show short positions or trades since then.
Who owns it
8 funds report owning VRXA
Insider trades · last 12 months
Real buys and sales
● Open-market buy● Open-market sale
Last 6 months. A wider screen shows 12.
Showing 2 real trades. Bigger dot means a bigger trade.
Real trades, newest first
Oct 28 Marc Gruninger Director Open-market buy $9.13K 9,133 sh at $1.00
Oct 27 Marc Gruninger Director Open-market buy $850 867 sh at $0.98
Showing every filing. Dashed circles are routine: grants, tax withholding, option exercises and planned sales.
Top holders
Biggest funds in VRXA
| Fund | Value | Change |
|---|---|---|
| UBS Group AG | $296K | |
| Geode Capital Management, LLC | $225K | |
| Susquehanna International Group, LLP | $20.4K | |
| Picton Mahoney Asset Management | $19.3K | |
| Wolverine Asset Management LLC | $3.29K |